Last reviewed · How we verify
csDMARDs
csDMARDs work by suppressing the immune system to reduce inflammation and slow disease progression in conditions such as rheumatoid arthritis.
csDMARDs work by suppressing the immune system to reduce inflammation and slow disease progression in conditions such as rheumatoid arthritis. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.
At a glance
| Generic name | csDMARDs |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | csDMARDs |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
csDMARDs, or conventional synthetic disease-modifying antirheumatic drugs, are a class of medications that have been used for decades to treat autoimmune diseases like rheumatoid arthritis. They work by suppressing the immune system to reduce inflammation and slow disease progression. This is achieved through various mechanisms, including the inhibition of cytokines and the modulation of immune cell function.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Juvenile idiopathic arthritis
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis (PHASE2)
- Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis (PHASE4)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs (PHASE3)
- Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis
- A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis (PHASE3)
- A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- csDMARDs CI brief — competitive landscape report
- csDMARDs updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI